NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
Clinical Trials
10 trialsNCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT01210482 2024-09-25
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT01367457 2016-04-27
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Pfizer
Completed
NCT00474786 2013-11-21
INTORSECT
Pfizer
Phase 3 Completed
NCT01781442 2013-05-01
A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
Pfizer
Withdrawn
NCT00065468 2012-10-25
ARCC
Pfizer
Phase 3 Completed
NCT00563147 2011-10-04
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00235794 2007-12-27
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Wyeth is now a wholly owned subsidiary of Pfizer
Phase NA Completed